These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 28663124

  • 21. [Vortioxetine: a new antidepressant to treat depressive episodes].
    Colle R, Corruble E.
    Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
    [Abstract] [Full Text] [Related]

  • 22. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W.
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
    Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y.
    Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
    Choi SE, Brignone M, Cho SJ, Jeon HJ, Jung R, Campbell R, Francois C, Milea D.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
    [Abstract] [Full Text] [Related]

  • 29. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
    Dziwota E, Olajossy M.
    Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
    [Abstract] [Full Text] [Related]

  • 30. [Vortioxetine in the treatment of major depression].
    de Bartolomeis A, Fagiolini A, Maina G.
    Riv Psichiatr; 2016 Nov; 51(6):215-230. PubMed ID: 27996982
    [Abstract] [Full Text] [Related]

  • 31. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
    Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E.
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
    [Abstract] [Full Text] [Related]

  • 32. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
    McIntyre RS, Lophaven S, Olsen CK.
    Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
    [Abstract] [Full Text] [Related]

  • 33. Vortioxetine for the treatment of major depressive disorder.
    Tritschler L, Felice D, Colle R, Guilloux JP, Corruble E, Gardier AM, David DJ.
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
    Fagiolini A, Florea I, Loft H, Christensen MC.
    J Affect Disord; 2021 Mar 15; 283():472-479. PubMed ID: 33516560
    [Abstract] [Full Text] [Related]

  • 36. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
    Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo ALC, Martinotti G, Vellante F, Matarazzo I, Vecchiotti R, Perna G, Di Nicola M, Carano A, Di Bartolomeis A, De Giannantonio M, De Berardis D.
    CNS Neurol Disord Drug Targets; 2017 Mar 15; 16(1):65-92. PubMed ID: 27781949
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.
    J Clin Psychiatry; 2010 Feb 15; 71(2):109-20. PubMed ID: 20193645
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
    Dubovsky SL.
    Expert Opin Drug Metab Toxicol; 2014 May 15; 10(5):759-66. PubMed ID: 24684240
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.